Pharmaceutical products

Tender description

NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B, Cytokine Modulators and other Monoclonal Antibodies, and Fondaparinux. Offer reference number: CM/PHR/16/5527 CM/PHR/16/5527/01 — Tranche B: 1.3.2020 to 28.2.2022 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5527/02 – Annual tranche — cytokine modulators and other monoclonal antibodies — 1.3.2020 to 28.2.2021 with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, South of England – 1.3.2020 – 31.8.2020, Midlands and East – 1.3.2020 – 28.2.2021, all with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5527/01 — 1.3.2020 to 28.2.2022 – NHS Framework for the NHS North of England Region, Branded Medicines – Tranche B with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. CM/PHR/16/5527/02 – 1.3.2020 to 28.2.2021 — NHS Framework for the NHS North of England Region, Branded Medicines – Annual Tranche — cytokine modulators and other monoclonal antibodies with an option to extend (at the authority’s discretion) for a period or periods up to a total of 12 months. CM/PHR/16/5527/03 – NHS framework agreement for Fondaparinux — London – 1.3.2020 – 31.8.2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. South of England – 1.3.2020 – 31.8.2020, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months. Midlands and East – 1.3.2020 – 28.2.2021, with an option to extend (at the authority’s discretion) for a period or periods up to a total of 24 months.